An observational study in ADHD - Attention Deficit Disorder With Hyperactivity, sponsored by Erasme University Hospital. Completed at 1 site in Belgium. Open to participants aged 6 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Erasme University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Attention Deficit Disorder with Hyperactivity with a site in Belgium — 1 open to participants now, 1 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Belgium.
Among the 24 studies in Attention Deficit Disorder with Hyperactivity with a site in Belgium, this one is the only one that started in 2025, is one of 2 observational ones, and was the 24th registered.
1,818 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 24 studies in Attention Deficit Disorder with Hyperactivity with a site in Belgium is open now. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 5–12 · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is close to the median of 130 across 330 observational studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 272 across the 22 interventional studies, 195 across the 2 observational. Of the 18 that completed or were terminated, 15 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 24 have an industry lead sponsor. The 10 most frequent:
Erasme University Hospital is the lead sponsor of 182 studies on the registry; 35 are open to participants now.
Erasme University Hospital has 1 study filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Attention Deficit Disorder with Hyperactivity with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most prevalent neurodevelopmental disorder in child and adolescent psychiatry, affecting approximately 8% of the population worldwide. Beyond the inattention, hyperactivity and impulsivity that define it in DSM-5, ADHD is consistently associated with attentional and executive deficits considered central to its symptomatology. Its aetiopathogenesis is multifactorial and remains poorly understood: decades of research have identified no specific genetic or environmental factor.
The gut microbiota modulates the bidirectional gut-brain axis, notably through the intestinal mucosa, which secretes neuromediators such as serotonin and precursors of dopamine implicated in concentration and in ADHD. Roughly ten case-control studies have reported differences in gut microbiota diversity, richness and composition between individuals with ADHD and typically developing individuals, and several have associated specific bacterial taxa with symptom severity. Methodological heterogeneity across these studies has so far precluded consensus on a specific bacterial signature. Critically, they relied almost exclusively on clinical questionnaires, which are subjective and vulnerable to respondent and observation bias, and did not assess the cognitive deficits that characterise the disorder. To date, no study has investigated the relationship between gut microbiota composition and cognitive performance measured with standardised neuropsychological tests in children with ADHD compared with typically developing children. This is the specific gap addressed here.
This monocentric, prospective, case-control observational study will enrol 140 French-speaking children aged 6 to 12 years: 70 children with ADHD, combined presentation, diagnosed according to DSM-5 criteria and recruited from the paediatric psychiatry clinics of the Hôpital Universitaire de Bruxelles (Erasme and HUDERF sites), and 70 typically developing children recruited through advertisements. Children are excluded for prematurity, IQ below 75, psychiatric or serious chronic disease, gastrointestinal or inflammatory bowel conditions, coeliac disease, food intolerances, eating disorders, dietary supplements within 4 weeks, and antibiotics, proton pump inhibitors or any psychotropic medication within 3 months, yielding a medication-free ADHD sample and removing major confounders of microbiota composition.
Each participant attends a single assessment visit. A stool sample is self-collected at home the day before or the day of the visit using a stabilising collection kit, then stored at -80 °C. Metagenomic DNA is extracted, the V1-V3 region of the 16S rRNA gene is amplified with universal eubacterial primers, amplicons are sequenced on an Illumina MiSeq platform, and reads are processed with the QIIME2 pipeline, in academic collaboration with the Louvain Drug Research Institute (UCLouvain). At the same visit, participants complete a cognitive assessment comprising the WISC-V (estimated IQ), selected subtests of the Test of Attentional Performance (visual and auditory selective attention, divided attention, vigilance, flexibility, Go/NoGo inhibition, working memory) and the Maudsley Index of Delay Aversion. ADHD symptom frequency and severity are rated by the physician using the ADHD Rating Scale IV, and dietary habits are documented with a Food Frequency Questionnaire completed before the visit.
The study has three objectives: to determine whether gut microbiota composition and diversity differ between children with ADHD and typically developing children, and to identify a possible imbalance or bacterial signature; to compare attentional and executive performance between the two groups and examine its association with microbiota composition; and to explore correlations between the severity of inattention and hyperactivity-impulsivity symptoms and microbiota composition. The hypotheses are that children with ADHD differ from typically developing children in microbiota diversity and composition, that they show poorer attentional and executive performance associated with their microbiota composition, and that their microbiota is associated with clinically rated symptom severity.
Background and rationale
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most prevalent neurodevelopmental disorder in child and adolescent psychiatry, affecting approximately 8% of the world population, and constitutes an unquestionable public health priority. Beyond the developmentally inappropriate levels of inattention, hyperactivity and impulsivity that define it in DSM-5, ADHD is consistently associated with executive and attentional deficits. These deficits lie at the heart of the explanatory models developed over the past twenty-five years, which converge on a predominant role for executive and attentional dysfunction in the symptomatology of the disorder. Its aetiopathogenesis is considered multifactorial with complex determinism, yet decades of research have been disappointing: neither specific genetic nor specific environmental factors have been formally identified.
Against this background, the exploration of a possible imbalance in gut microbiota composition - induced by diet or by other environmental factors - represents a new and original approach to understanding the aetiopathophysiology of ADHD and to identifying promising leads for novel prevention and treatment strategies.
The digestive system, sometimes called the "second brain", contains roughly 100 million neurons distributed along its length and forms part of the autonomic nervous system. It maintains bidirectional relationships with the central nervous system and plays a role in the regulation of digestive motility, nutrient absorption and control of the intestinal barrier. Recent research on the gut microbiota has transformed our understanding of the balance between the micro-organisms that compose it and their mutualistic relations with the host. Beyond its role in general health, the gut microbiota is implicated in the modulation of the gut-brain axis: it acts on the intestinal mucosa, which secretes neuromediators involved in the management of stress and emotion, such as serotonin, as well as dopamine precursors implicated in concentration and in ADHD.
The gut microbiota can be degraded - or conversely rebalanced - by external factors (diet, medication, stress, age, environment) that influence the quantity, richness, diversity and bacterial composition of the ecosystem. Microbiota alterations and the emergence of bacterial signatures have been consistently reported across neurological, neurodevelopmental, neurodegenerative and neuropsychiatric disorders. In ADHD specifically, research remains limited. The fact that individuals with ADHD experience gastrointestinal dysfunction - notably digestive difficulties during childhood, low-grade inflammation and constipation - suggests a potential role for the gut microbiome in the disorder. Dietary interventions are also attracting growing interest for their potential to attenuate ADHD symptoms, possibly by reducing subclinical allergic reactions or inflammation, as children with ADHD show increased susceptibility to allergies.
To date, approximately ten studies have compared the gut microbiota of individuals with ADHD with typically developing control groups. Collectively they reveal significant variations in bacterial composition, diversity and richness between the two populations. A systematic review identified 49 bacterial taxa showing significant differences between individuals with ADHD and typically developing individuals, including genera such as Bifidobacterium, Dialister and Faecalibacterium; two meta-analyses have reported significant differences in microbial diversity in people with ADHD. However, methodological divergences and biases across these studies preclude any consensus on a definitive association between microbiota imbalance and ADHD, or on the identification of a specific bacterial signature.
Several studies have additionally reported links between ADHD symptom severity and microbiota variation, identifying bacterial species and genera associated with the intensity of inattention and/or hyperactivity-impulsivity symptoms as rated by peers, parents or the individuals themselves. For example, an association has been observed between the abundance of the genus Ruminococcus and the severity of inattention symptoms, and between the abundance of two other genera and the intensity of hyperactivity-impulsivity symptoms. Results vary across studies and symptom categories, but these observations carry important clinical implications: they suggest that the gut microbiota may play a role in the expression of ADHD, and that symptomatology could be favourably influenced by rebalancing the microbiota or by therapies targeting specific bacteria.
Critically, the studies cited above have explored the gut-brain axis primarily through clinical questionnaires - subjective instruments susceptible to respondent-related bias and to the conditions of observation. It is likely that assessing the bidirectional interactions between ADHD and the gut microbiota through behavioural scales alone cannot rigorously or specifically characterise the nature of these links. Cognitive deficits, particularly in the executive and attentional domains, are not captured by these approaches.
To date, no study has investigated the relationships between gut microbiota composition and cognitive performance assessed with standardised neuropsychological tests in individuals with ADHD compared with typically developing individuals. The present study is original precisely in this respect: it seeks to explore the interactions between the gut microbiota and cognitive functioning in ADHD, focusing on the domains identified as impaired in ADHD and considered central to its symptomatology - divided and selective attention, inhibition, cognitive flexibility, working memory, vigilance, delay aversion, and reaction time variability.
Hypotheses Children with ADHD will show a gut microbiota composition significantly different from that of typically developing children, in terms of both diversity and composition.
Children with ADHD will show significantly poorer attentional and executive performance than typically developing children, and these performances will be associated with participants' gut microbiota composition.
The gut microbiota of children with ADHD will be associated with symptom severity as rated by clinical scales, and above all by clinical medical observation.
Objectives To explore whether gut microbiota composition differs in children with ADHD aged 6-12 years compared with typically developing children, in order to identify a possible imbalance and/or bacterial signature in ADHD participants.
To compare the cognitive performance of the two groups (ADHD vs. typically developing) on attentional and executive tasks, and to examine the associations of these performances with gut microbiota composition.
To explore the correlations between the severity of inattention and hyperactivity-impulsivity symptoms and gut microbiota composition.
Outcome measures
The source protocol does not formally designate primary and secondary endpoints. The following mapping is proposed for the registration record and should be confirmed by the investigator team before submission.
Primary outcome measures (time frame: baseline, T0 - single assessment)
Gut microbiota alpha diversity, compared between the ADHD and typically developing groups.
Gut microbiota beta diversity, compared between groups. Relative abundance of bacterial taxa at genus level, compared between groups.
Secondary outcome measures (time frame: T1 - single assessment)
Attentional and executive performance on the Test of Attentional Performance (TAP, version 2.3) subtests - visual and auditory selective attention, divided attention, vigilance, flexibility, inhibition (Go/NoGo) and working memory - compared between groups, and correlated with microbiota diversity and taxa abundance.
Delay aversion measured by the Maudsley Index of Delay Aversion (MIDA), compared between groups and correlated with microbiota measures.
ADHD symptom severity measured by the ADHD Rating Scale IV (ADHD-RS-IV), total score and inattention and hyperactivity-impulsivity subscale scores, correlated with microbiota diversity and taxa abundance within the ADHD group.
Estimated IQ derived from the WISC-V, used as a descriptive and covariate measure.
Dietary habits measured by the Food Frequency Questionnaire (FFQ), used as a covariate in microbiota analyses.
Study design
Study procedures and assessments
All assessments take place at a single study visit (T0), with the dietary questionnaire completed in the week before (T1) and again the day before the visit.
Clinical evaluation. Medical data and DSM-5 criteria for ADHD, together with a paedopsychiatric examination validating the ADHD diagnosis according to standardised international criteria, with exploration of clinical comorbidities in order to exclude them.
ADHD Rating Scale IV (ADHD-RS-IV). A scale measuring the frequency of occurrence and the severity of ADHD symptoms, completed by the physician during the consultation.
Food Frequency Questionnaire (FFQ). Used to document the dietary habits of participants - a non-negligible factor in the study of the gut microbiota. Completed one week before the visit and again the day before.
Cognitive assessment (all participants).
Intellectual functioning: Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V). An abbreviated IQ, referred to as "estimated IQ", is computed.
Attentional and executive functions: the Test of Attentional Performance (TAP, version 2.3) battery provides computerised assessment of several cognitive parameters. Subtests selected on the basis of the existing scientific literature on cognitive profiles in ADHD are: visual and auditory selective attention, divided attention, vigilance, flexibility, inhibition (Go/NoGo) and working memory.
Delay aversion: the Maudsley Index of Delay Aversion (MIDA). Stool collection and microbiota analysis
Stool destined for gut microbiota analysis is collected on the day of the visit or the day before. Collection is performed at home, in a dedicated collection kit (OMNIgene·GUT, OMR-200, DNA Genotek). The sample can remain unfrozen for up to 60 days at ambient temperature in the stabiliser. It is brought to the consultation and stored in a -80 °C freezer. Once all samples have been collected, analysis is carried out in a laboratory within an academic collaboration.
Laboratory analyses of the gut microbiota and the associated statistical analyses are performed within an academic collaboration with Prof. Dr Amandine Everard, Research Associate FRS-FNRS, WELBIO (Walloon Excellence in Life Sciences and Biotechnology), Louvain Drug Research Institute, Metabolism and Nutrition (UCLouvain / LDRI / MNut), Av. E. Mounier 73 box B1.73.11, B-1200 Brussels, Belgium.
Metagenomic DNA is extracted from stool using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, with modifications. The V1-V3 region of the 16S rRNA gene is amplified using the following universal eubacterial primers: 27Fmod (5'-AGRGTTTGATCMTGGCTCAG-3') and 519Rmodbio (5'-GTNTTACNCGCGGCKGCTG-3'). Purified amplicons are sequenced on an Illumina MiSeq platform. Sequence reads are demultiplexed and processed using the QIIME2 pipeline. Biostatistical analyses are performed within this laboratory by bioengineers competent in this specific field.
Data collection, handling and protection
Data are collected using the internal REDCap software in the form of an eCRF, in which the identification code of each participant is requested. Variables containing personally identifying information are encoded as "identifiers" and are not exportable for data analysis. Data collection is strictly limited to the data necessary for the research, and is organised so that re-identification of the patient through data linkage is impossible.
Personal data for each participant are pseudonymised and replaced by a code allowing the link between the participant's identity in anonymous form within the research and the patient's medical record. The code contains no element permitting recognition of the patient. Only the principal investigator, Dr Isabelle Massat, holds this correspondence database, in the form of an Excel file protected by a password and stored on the Erasme site. For confidentiality reasons, the file will be destroyed once the results are published.
Risks and benefits
Risks. No risk is incurred by participants.
Potential benefits. Advancement of knowledge on the gut microbiota in ADHD and in typically developing individuals, and on attentional and executive alterations in ADHD in relation to the gut microbiota. No procedure or examination is billed to the patient beyond usual clinical practice (clinical follow-up consultations). The results of the cognitive tests are provided to the family, at no charge, via the physician who usually coordinates the patient's care, or by the neuropsychologist who conducted the assessment, as in routine clinical practice.
Regulatory and ethical framework
The study is conducted in accordance with Good Clinical Practice, the Declaration of Helsinki, and the moral, ethical and scientific principles justifying medical research, and in accordance with all relevant laws and regulations relating to clinical studies and the protection of patients. Ethics Committee review and approval requirements are met, and any changes in research activity, as well as all unanticipated problems involving risks to human subjects, are promptly reported to the Ethics Committee. The sponsor is CUB - Hôpital Erasme.
Children aged 6 to 12 years with ADHD, combined presentation (n = 70), and children of the same age with typical development (n = 70). ADHD participants are recruited from the paediatric psychiatry outpatient clinics of the Hôpital Universitaire de Bruxelles (HUB) across its two sites, Erasme and HUDERF, under the supervision of Dr Massat. Typically developing participants are recruited through advertisements and the investigators' networks.
The 6-12 year age band was selected for two reasons: it is the age range in which ADHD is most frequently diagnosed, and dietary intake can be reported more reliably by parents in this age group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child with ADHD
Child with a normal develop
ADHD-RS IV
Scale that measures the frequency of occurrence and severity of ADHD symptoms. ADHD Assessment Kit by the Canadian ADHD Resource Alliance (CADDRA)(DuPaul et al., 1998)
Time frame: baseline
Food Frequency Questionnaire (FFQ)
Questionnaire on the various foods consumed and their frequency over 12 months (De Keyzer et al., 2013)
Time frame: One week after the start
IQ Test
IQ measurement with WISC-V
Time frame: One week after the start
Test of Attentional Performance (TAP)
Computerized assessment of various cognitive parameters. In view of the existing scientific literature on cognitive profiles in ADHD (Khaledi et al., 2019; Pievsky \& McGrath, 2018), the following subtests were selected: Visual and auditory selective attention, divided attention, vigilance, flexibility, inhibition (Go/NoGo) and working memory.
Time frame: One week after the start
The Maudsley Index of Delay Aversion
MIDA will be used to assess delay aversion (MIDA; Kuntsi et al., 2001).
Time frame: One week after the start
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2025 to primary completion in Aug 2026, 10 months.
Of 86 non-industry observational studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's 10 months is below that.
Counting every sponsor, half of 96 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →